allergytalk (allergytalk)

Show details Episodes (76)Links (147)RSS Check (48%)Related content (26)

Explore every episode of allergytalk

Dive into the complete episode list for allergytalk. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.

	Pub. Date	Title	Duration
	02 Oct 2019	•Episode 5: Risk Factors for Venom Allergy, Triggers for Adult-onset Asthma and Associations Between Pollution and ED Visits	00:29:32
This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch: Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms https://www.ncbi.nlm.nih.gov/pubmed/30819281 New-Onset Asthma in Adults: What Does the Trigger History Tell Us? https://www.ncbi.nlm.nih.gov/pubmed/30240884 Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States https://www.ncbi.nlm.nih.gov/pubmed/30277796 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from AstraZeneca. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	21 Dec 2023	Episode 26: Do Airborne Peanuts Cause Allergic Reactions? July/Aug 2021	00:28:21
For today’s episode we will be reviewing articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Articles Reviewed: When an asthma patient doesn’t respond to biologic, what should we do? Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy . Can we reduce lung function loss in asthma? Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. Airborne peanut doesn’t cause clinical significant reactions Peanuts in the air - clinical and experimental studies. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. At the time of recording, the speakers had the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, Alladapt, Novartis
	21 Jan 2022	Moving Towards Equity: Disparities in PIDD, Episode 3: Improving Access to Treatment for PIDD in Minority and Underserved Populations	00:23:36
This episode will outline barriers to immune globulin and transplantation and offer solutions
	07 Jan 2021	Episode 14: Food allergy and anaphylaxis, plus success of peanut OIT	00:26:18
For today’s episode we will be reviewing three articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article links: Earlier Ingestion of Peanut After Changes to Infant Feeding Guidelines: The EarlyNuts Study Effect of Sleep Deprivation and Exercise on Reaction Threshold in Adults With Peanut Allergy: A Randomized Controlled Study Treatment With a Platelet-Activating Factor Receptor Antagonist Improves Hemodynamics and Reduces Epinephrine Requirements, in a Lethal Rodent Model of Anaphylactic Shock Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	17 Oct 2024	The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 2	00:18:33
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma Host: Gerald B. Lee, MD, FACAAI Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges. Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252. Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose William C. Anderson III, MD, FACAAI Advisor: Genentech, Regeneron, Sanofi Leonard B. Bacharier, MD, FACAAI Advisor: DBV Technologies Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Researcher: AstraZeneca, Sanofi Speaker: Regeneron, Sanofi This podcast miniseries is supported by a grant from AstraZeneca.
	16 Jul 2024	Episode 43 – Does Allergen Immunotherapy Improve Anti-viral Immunity?	00:20:47
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation. Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Spriet have nothing to disclose Dr. Fineman: Research: DBV, Novartis, Alladapt
	26 May 2020	Episode 11: Step Up Therapy In Asthma, A Therapy For Habit Cough	00:34:42
For today’s episode we will be reviewing three articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk Article links: Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate. Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. Unexpected and unintended cure of habit cough by proxy. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	11 Jun 2024	Episode 33: Are We Testing for Hymenoptera Backwards?	00:21:36
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Vivan Hernandez-Trujillo, MD from Nicklaus Children’s Hospital in Miami, Florida where we review the July-Aug 2022 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Combining Discordant Serum IgE and Skin Testing Improves Diagnostic and Therapeutic Accuracy for Hymenoptera Venom Hypersensitivity Immunotherapy. Safety of Live Attenuated Influenza Vaccine in Children With Asthma. Obesity alters pathology and treatment response in inflammatory disease. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Hernandez-Trujillo: Speaker Takeda, CSL Advisory boards Takeda, Regeneron, Sanofi Consultant Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network Dr. Fineman: Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	10 Feb 2020	Episode 7 - Part I: An Interview with Dr. Brian Vickery	00:30:05
We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.
	03 Jul 2024	Episode 38: Should Immunotherapy Be Offered For Atopic Dermatitis?	00:28:16
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch . Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. The impact of prenatal dog keeping on infant gut microbiota development. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Rathkopf have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	13 Dec 2024	Episode 47: Does Food Allergy Increase Cardiovascular Risk?	00:24:57
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! CRISPR Gene-Editing Therapy for Hereditary Angioedema Reviewed by Samantha knox CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975. New Peanut Allergy Rare After Peanut Introduction in Infants Reviewed by Sarah Spriet Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248. IgE to Food Allergens and Cardiovascular Mortality Reviewed by Gerry Lee IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097. Please rate our podcast on Apple podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)
	20 Jun 2024	Episode 35: Can Azithromycin Help Poorly Controlled Childhood Asthma?	00:21:51
Originally Recorded 4/18/2023 Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Articles Reviewed: In Kids With Allergic Rhinitis, Remember To Address Sleep Problems! Allergic disease, sleep problems, and psychological distress in children recruited from the general community. Azithromycin as an Option for Poorly Controlled Childhood Asthma Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial. Data Suggest ‘Real-World Benefit’ of Early Introduction Changes in Australian food anaphylaxis admission rates following introduction of updated allergy prevention guidelines. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Joshi has the following disclosures: Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent Clinical trial funding: GlaxoSmithKline Sanofi Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	09 Apr 2020	Episode 9: Asthma Epidemiology, Diet, and More on MART Therapy	00:27:41
For this episode, we will be reviewing three articles about asthma from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk Article Links: Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	13 Dec 2024	Episode 46: Can We Achieve Clinical Remission In Asthma?	00:24:35
Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Reviewed by Iris Otani Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839. Clinical Remission in a Real-World Severe Asthma Registry Reviewed by Tim Chow Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453. More Evidence Against Using Corticosteroids for Anaphylaxis Reviewed by Iris Otani Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113. Please rate our podcast on Apple podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)
	13 Dec 2024	Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE	00:12:44
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed. Learning Objective: After listening to this podcast episode, participants should be better able to: Employ strategies for long-term prophylaxis. References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022 Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva This podcast miniseries is supported by a grant from Takeda.
	13 Mar 2020	Episode 8 - Part 1: How the College Supports Allergists - Education and Advocacy	00:29:47
Welcome to Episode 8 of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! At the 2019 ACAAI Annual Meeting in Houston, Texas we interviewed the leaders of the College on how the ACAAI helps its members and what to expect for 2020! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Mahr: Research / Consultant / Advisory Board / Speaker / Honorarium: Aimmune, ALK, AZ, Boeringer-Ingelheim, Kaleo, GSK, Optinose, Sanofi-Genzyme - Regeneron Dr. Meadows: Speaker: Regeneron, Pfizer, AZ, GSK, Optinose Consultant: Aimmune Dr. Lee: No relevant disclosures
	11 May 2023	Severe Pediatric Asthma Miniseries - Episode 3	00:30:28
Episode 3: Severe pediatric asthma-beyond standard therapy, the role of current and future therapies including biologics Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden. Learning Objectives: Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma References: Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019). Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)
	26 Jun 2024	Episode 37: Is There a Role For Allergen Immunotherapy in Seasonal Allergic Asthma? Jan/Feb 2023	00:26:40
Today we joined by Dr. Samanta Knox, MD from Gunderson Health System in La Crosse, WI where we review the Jan-Feb 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study. Prospective evaluation of tolerance to unheated milk-boiled egg after baked milk-egg tolerance under 2 years. Multiscale study of the oral and gut environments in children with high- and low-threshold peanut allergy. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Knox have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	20 Dec 2023	AllergyTalk Episode 32: How Does the Atopic March Differ in Black and White Children?	00:26:42
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children’s Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Hernandez-Trujillo: Speaker Takeda, CSL Advisory boards Takeda, Regeneron, Sanofi Consultant Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	16 Jan 2025	Episode 48 - Can Blood Transfusions Trigger Food Allergy?	00:19:19
Welcome to Season Three of Allergytalk! Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins. Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant/Speaker: Kaleo Consultant: Allergy & Asthma Network, Pharming Speaker: CSL, Takeda
	09 Apr 2020	Episode 10: OIT Safety, OR Anaphylaxis, and IT for Cats	00:30:57
For this episode, we will be reviewing three articles from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk Article Links: Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study. Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	11 Sep 2024	Episode 44 - How Does Tryptase Genetics Affect Food Allergy Reactions?	00:27:09
Welcome to Season Three of Allergytalk! Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Outcomes of oral food challenges in a real-world setting, with predictors of outcomes. Severe food allergy reactions are associated with α-tryptase. Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis. Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
	13 Aug 2021	AllergyTalk Episode 21: T2 inflammation in CRSsNP, IgG Levels Differ By Gender/Race	00:32:22
For today’s episode we will be reviewing articles from the November-December 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype. Novel airway smooth muscle-mast cell interactions and a role for the TRPV4-ATP axis in non-atopic asthma. Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	09 Sep 2020	Episode 13, Part 1 – Delayed Drug Hypersensitivity with Dr. David Khan, MD	00:28:31
Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org! The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.
	20 Dec 2023	Episode 31: The Presentation of an Inborn Error of Immunity Is Not Always Infection!	00:27:33
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are again joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Montanaro has done research with AstraZeneca, Regeneron, Theravance, and Teva Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst, Novartis
	09 Jul 2024	Episode 41 – A Promising New Treatment for SCID!	00:22:58
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic Rhinitis. Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Chow have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	20 Dec 2023	Episode 30: Is COVID Vaccine Skin Testing Useful?	00:30:39
Welcome to Season Two of Allergytalk! Starting with this episode, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. Differences in oral food challenge reaction severity based on increasing age in a pediatric population. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
	15 Mar 2021	Episode 19 - Using Fractional Exhaled Nitric Oxide to Guide Step-down Treatment Decisions	00:28:34
For today’s episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging discussion with the opportunity for ongoing conversation about today's topic! Article links: Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial. Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	14 Jun 2022	Disparities in Atopic Dermatitis Miniseries: Episode 3: Improving Access to Treatment for Atopic Dermatitis in Minority and Underserved Populations	00:19:34
This episode will describe best practices for addressing disparities in care for patients with atopic dermatitis and how to implement specific health equity strategies to improve access to atopic dermatitis care and increase patient adherence to treatment. Disparities in Atopic Dermatitis Miniseries Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI The miniseries is hosted by Payel Gupta, MD, a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center. She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children’s Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis. This podcast series is supported by Pfizer.
	27 Mar 2020	Episode 8 part 2 - How the College Supports Allergists - Practice Management	00:15:09
Welcome to Episode 8, part 2 of Allergy Talk! I sat down with my co-host Stan Fineman, MD, MBA, ACAAI to review the practice management resources from the ACAAI! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron. Dr. Lee has no relevant disclosures.
	14 Jun 2022	Disparities in Atopic Dermatitis Miniseries: Episode 1: Current Evidence for Disparities in Atopic Dermatitis	00:19:03
This episode will review racial, ethnic, socioeconomic, and geographic disparities related to atopic dermatitis. Disparities in Atopic Dermatitis Miniseries Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI The miniseries is hosted by Payel Gupta, MD, a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center. She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children’s Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis. This podcast series is supported by Pfizer.
	26 Jun 2024	Episode 36: How Safe Are Oral Corticosteroids? Jan/Feb 2023	00:22:15
Today we joined by Dr. Samanta Knox, MD from Gunderson Health System in La Crosse, WI where we review the Jan-Feb 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can earn CME credit by listening to this podcast! For information about CME credit, go to https://education.acaai.org/allergytalk. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Race and ethnicity define disparate clinical outcomes in chronic rhinosinusitis. Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study. Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Knox have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	08 Jun 2021	AllergyTalk Episode 20: Methacholine Challenge Caveats, Biologic Super-Responders	00:34:28
For today’s episode we will be reviewing articles from the November-December 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE. Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	10 Feb 2020	Episode 7 - Part II: An Interview with Dr. Brian Vickery	00:37:46
We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org
	21 Jan 2022	Moving Towards Equity: Disparities in PIDD, Episode 2: Addressing the Barriers to Diagnosis of PIDD in Minority and Underserved Populations	00:17:38
This episode will outline each barrier discussed in podcast #1 and then offer resources and solutions
	14 Jun 2022	Disparities in Atopic Dermatitis Miniseries: Episode 2: The Influence of Skin of Color in Diagnosing and Managing Patients With Atopic Dermatitis	00:21:39
This episode will describe the influence of skin color in diagnosing and managing patients with atopic dermatitis. Disparities in Atopic Dermatitis Miniseries Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI The miniseries is hosted by Payel Gupta, MD, a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center. She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children’s Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis. This podcast series is supported by Pfizer.
	31 Jan 2025	Episode 49 – AllergyWatch July/August 2024	00:22:05
Welcome to Season Three of AllergyTalk! Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: The mental health burden of food allergies: Insights from patients and their caregivers from the Food Allergy Research & Education (FARE) Patient Registry. Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders. Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant: Pharming, Kaleo Speaker: CSL, Takeda, Kaleo
	23 Mar 2023	CRSwNP Miniseries: Episode 1	00:14:23
Episode 1 provides an overview of the subtypes of CRSwNP and reviews the evidence for disparities in the burden of disease on minority and underserved populations and discusses the reasons for these disparities. Today’s speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose This podcast series is supported by Sanofi Regeneron.
	17 Oct 2024	The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 1	00:13:31
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 1: The Limitations of Bronchodilator Only Rescue Therapy Host: Gerald B. Lee, MD, FACAAI Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy. Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252. Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose William C. Anderson III, MD, FACAAI Advisor: Genentech, Regeneron, Sanofi Alan P. Baptist, MD, MPH, FACAAI Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Researcher: AstraZeneca, Novartis, Regeneron This podcast miniseries is supported by a grant from AstraZeneca.
	13 Dec 2024	Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies Miniseries Episode 1 – Diagnosing HAE Accurately	00:16:02
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed. Learning Objective: After listening to this podcast episode, participants should be better able to: Diagnose pediatric HAE accurately References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022 Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia Timothy J. Craig, DO, FACAAI Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda Independent Contractor: Kalvista, Phavaris Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda This podcast miniseries is supported by a grant from Takeda.
	17 Oct 2024	The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 3	00:22:44
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma Host: Gerald B. Lee, MD, FACAAI Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application. Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252. Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Leonard B. Bacharier, MD, FACAAI Advisor: DBV Technologies Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Researcher: AstraZeneca, Sanofi Speaker: Regeneron, Sanofi Alan P. Baptist, MD, MPH, FACAAI Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Researcher: AstraZeneca, Novartis, Regeneron This podcast miniseries is supported by a grant from AstraZeneca.
	18 Feb 2021	Episode 16: Comorbid Laryngeal Dysfunction in Asthma	00:29:15
Show notes for Episode 16: For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic! Article links: Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis. Trends and Disparities in Asthma Biologic Use in the United States. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	24 Mar 2022	AllergyTalk Episode 23 – Revisiting Acetaminophen and Asthma, Poor Perceivers of Dyspnea	00:22:33
For today’s episode we will be reviewing articles from the January-February 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Early life acetaminophen exposure, glutathione S-transferase genes, and development of adolescent asthma in a high-risk birth cohort. Health Services Utilization Is Increased in Poor Perceivers of Bronchoconstriction and Hyperinflation in Asthma. Milk allergy most burdensome in multi-food allergic children.
	13 Dec 2024	Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 2 – Overcoming Barriers in HAE Treatment	00:20:13
Episode 2: Overcoming Barriers in HAE Treatment Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration. Learning Objective: After listening to this podcast episode, participants should be better able to: Create effective treatment plans for their specific population (minority, rural, urban) References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022 Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva Timothy J. Craig, DO, FACAAI Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda Independent Contractor: Kalvista, Phavaris Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda This podcast miniseries is supported by a grant from Takeda.
	11 May 2023	Severe Pediatric Asthma Miniseries - Episode 1	00:18:18
Episode 1: Severe pediatric asthma-burden of disease, adherence issues, and comorbidities Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden. Learning Objectives: Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma References: Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019). Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)
	21 Dec 2023	Episode 28: Is IBS a Type of Food Allergy? Nov/Dec 2021	00:28:26
For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Metabolic Changes During Anaphylaxis Vary by Triggers and Severity Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers. Is IBS Caused by Local Food Allergy in the Intestine? Local immune response to food antigens drives meal-induced abdominal pain. Biologics: To Stop or Not to Stop, That Is the Question Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. At the time of recording, the speakers had the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	16 Nov 2021	AllergyTalk Episode 22 – Could Anti IL-5 Make Asthma Worse?, Egg OIT vs. Baked Egg for Egg Allergy	00:30:35
For today’s episode we will be reviewing articles from the January-February 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	11 Sep 2024	Episode 45 - Should We Wait To Skin Test After A Food Allergy Reaction? AllergyWatch Jan/Feb 2024	00:24:56
Welcome to Season Three of Allergytalk! Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Gut microbiota maturity mediates the protective effect of siblings on food allergy. Duration of skin prick test refractory period following food-induced allergic reactions. Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis. Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
	04 Jun 2024	Episode 27: How Important Is Family History in Infant Peanut Allergy?	00:24:28
Originally recorded 11/24/21 For today’s episode we will be reviewing three articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Is Alpha-Gal Really a Problem in Patients with Food Allergy? Diagnostic testing for galactose -alpha-1,3-galactose , United States, 2010 to 2018. Family history alone isn’t a Risk Factor for Peanut Allergy Age and eczema severity , but not family history, are major risk factors for peanut allergy in infancy. Peripheral eosinophil counts: a moving target Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. At the time of recording, the speakers had the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	11 May 2023	Severe Pediatric Asthma Miniseries - Episode 2	00:22:24
Episode 2: Severe pediatric asthma-evaluation of the child, diagnostic testing, assessing steroid side effects Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden. Learning Objectives: Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma References: Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019). Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)
	23 Mar 2023	CRSwNP Miniseries: Episode 2	00:13:35
Episode 2 discusses the impact of air pollution and the environment on CRSwNP and how this disproportionately affects minority and underserved populations. Today’s speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose This podcast series is supported by Sanofi Regeneron.
	21 Jan 2022	Moving Towards Equity: Disparities in PIDD, Episode 1: Underdiagnosis of PIDD in Minority and Underserved Populations	00:13:54
This episode will review the current evidence of underdiagnosis of PIDD in minority/underserved populations. Episode may include interview clips from a patient on how they/their children received the diagnosis of PIDD and what barriers they experienced in receiving the diagnosis of PIDD and what barriers they experienced in receiving the diagnosis of PIDD.
	03 Jul 2024	Episode 39: Should We Pay Teenagers to Carry Epinephrine?	00:29:51
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch . Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Food Allergy Management for Adolescents Using Behavioral Incentives: A Randomized Trial. Early, continuing exposure to cow's milk formula and cow's milk allergy: The COMEET study, a single center, prospective interventional study. Determinants of lung function across childhood in the Severe Asthma Research Program (SARP) 3. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Rathkopf have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	24 Mar 2022	AllergyTalk Episode 24 – Exercise Should Be Standard Asthma Management, Tips for Chronic Cough	00:28:49
For today’s episode we will be reviewing articles from the May-June 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: A Behavior Change Intervention Aimed at Increasing Physical Activity Improves Clinical Control in Adults With Asthma: A Randomized Controlled Trial. The Predicative Clinical Features Associated with Chronic Cough That Has a Single Underlying Cause. Trends in US hospitalizations for anaphylaxis among infants and toddlers: 2006 to 2015.
	02 Mar 2024	Omalizumab for Food Allergy Part 2: Implementation Into Practice	00:29:43
Welcome to a special 2 part episode of Allergytalk! On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In second part of a 2 part series, we will discuss important considerations in implementing omalizumab for food allergy in your practice. Speakers: Dr. Sharon Chinthrajah, MD, an associate professor at Stanford University and the Director of the Sean N Parker Center for Allergy and Asthma Research. She is a co-chair of the OUtMATCH study. Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study. Important Links: Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382 Updated FDA label for omalizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose. Dr. Chinthrajah has consulted for Genentech and Novartis. Dr. Vickery has consulted for Genentech and Novartis
	30 Apr 2020	Cough Miniseries – Episode 3: Treatment Options Cough	00:18:45
In the third of three podcasts focusing on Cough, host Dr. Purvi Parikh joins with Dr. Kevin Murphy and Dr. Mandel Sher to look at the what does and doesn’t work in treating cough. They review the current therapies and what new therapies options are coming in the future. This podcast is supported by an educational grant from Merck & Co., Inc. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron Purvi Parikh, MD Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca Mandel Sher, MD Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe
	23 Mar 2023	CRSwNP Miniseries: Episode 3	00:15:06
Episode 3 discusses access to treatment disparities for nasal polyposis in minority and underserved populations. Today’s speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose This podcast series is supported by Sanofi Regeneron.
	14 Aug 2024	AllergyTalk Special Episode: Preparing For the Allergy/Immunology Boards	00:41:01
Welcome to a Special Board Review Episode of AllergyTalk! As the fall welcomes a new class of allergy/immunology fellows, the graduating fellows are studying for the fall ABAI board certification exam. I’m excited to be joined by the editorial team of the newly released 5th edition of the ACAAI Review of the Allergy & Immunology Boards, where we’ll talk about how you can prepare for the upcoming board exam! Guests: Joyce Yu, MD Associate Professor of Pediatrics Director, Food Allergy Center Division of Allergy, Immunology and Rheumatology Columbia University Irving Medical Center Ben Prince, MD, MSCI Associate Professor of Pediatrics Associate Division Chief of Research Division of Allergy-Immunology The Ohio State University College of Medicine Resources for Board Review: Exam Blueprint ACAAI FIT and Board Review Resources (including the board review book) AIM Self-Assessment: Volume One (2023) AAAAI Allergy/Immunology Self Assessment For information about CME credit, head over to http://education.acaai.org/allergytalk Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis. Dr. Prince is a Data Monitoring Committee Member for Eli Lilly Dr. Yu has no relevant disclosures.
	18 Feb 2021	Episode 17: Reintroduction Failure after Negative Food Challenges	00:29:59
For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic! Article links: Reintroduction failure after negative food challenges in adults is common and mainly due to atypical symptoms. Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy. Home self-monitoring in patients with asthma using a mobile spirometry system. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	30 Apr 2020	Cough Miniseries – Episode 2: Diagnosing the Patient's Cough	00:29:57
In this, the second of three podcasts focusing on Cough, host Dr. Purvi Parikh discusses diagnosing cough with Dr. Mandel Sher and Dr. Kevin Murphy. They address diagnosing chronic cough in children and adults. Protracted bacterial bronchitis, the role of GERD in cough, and habit cough are also discussed. This podcast is supported by an educational grant from Merck & Co., Inc. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron Purvi Parikh, MD Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca Mandel Sher, MD Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe
	02 Mar 2024	Omalizumab for Food Allergy Part 1 : Reviewing the Evidence	00:37:51
Welcome to a special 2 part episode of Allergytalk! On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part of a 2 part series, we will review the evidence behind the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH) study that led to this FDA indication. In Part II, we will discuss important considerations in implementing omalizumab for food allergy in your practice. Speakers: Dr. Robert Wood, MD, the Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology and Division Director at Johns Hopkins University School of Medicine and Primary Investigator of the OUtMATCH study. Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study. Important Links: Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, YovetichN, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382 Updated FDA label for omalizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose. Dr. Wood has consulted for Genentech. Dr. Vickery has consulted for Genentech and Novartis
	30 Apr 2020	Cough Miniseries – Episode 1: Understanding the Cough Reflex	00:21:37
In this, the first of three podcasts focusing on Cough, host Dr. Purvi Parikh speaks with Dr. Mandel Sher and Dr. Kevin Murphy about the “true” cough reflex, the cough response, and cough hypersensitivity. This podcast is supported by an educational grant from Merck & Co., Inc. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron Purvi Parikh, MD Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca Mandel Sher, MD Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe
	21 Dec 2023	Episode 25: Is Cefazolin Safe in Penicillin Allergic Patients? May/June 2021	00:26:10
For today’s episode we will be reviewing articles from the May-June 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Articles Reviewed: AZT Improves Outcomes and Lowers Costs in Uncontrolled Asthma The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. Cefazolin Should Be Used in Most Penicillin Allergic Patients Assessment of the Frequency of Dual Allergy to Penicillins and Cefazolin : A Systematic Review and Meta-analysis. Consider IV Fluids Early if Anaphylaxis Doesn’t Respond to Epinephrine Cardiovascular changes during peanut-induced allergic reactions in human subjects. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. At the time of recording, the speakers had the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	26 May 2020	Episode 12 - Changing Biologics, Mucus Viscosity, Pemphigus and Food Allergy	00:32:22
For today’s episode we will be reviewing three more articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk Article Links: The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Altered Viscosity of Nasal Secretions in Postnasal Drip. Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a "hit-and-run" mechanism. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	18 Feb 2021	Episode 15: Prenatal Exposure to Air Pollution	00:30:02
For today’s episode we will be reviewing three more articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article links: Prenatal and Early-Life Exposure to Indoor Air-Polluting Factors and Allergic Sensitization at 2 Years of Age Impact of Sinus Surgery on Type 2 Airway and Systemic Inflammation in Asthma Long-term Sublingual Immunotherapy for Peanut Allergy in Children: Clinical and Immunologic Evidence of Desensitization Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	21 Dec 2023	Episode 29: A New Asthma Biologic, Biomarkers for AERD, mHealth for Asthma Nov/Dec 2021	00:28:55
For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Articles Reviewed: Tezepelumab Reduces Exacerbations – Even at Lower Eosinophil Counts Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma . Predicting Response to Aspirin Therapy in NSAID-ERD Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease. Can Technology Aid in Asthma Therapy Adherence? The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. At the time of recording, the speakers had the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	15 Mar 2021	Episode 18 - Asthma severity and Difficulty Learning to Read	00:29:15
For today’s episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways with the opportunity for ongoing conversation about today's topic! Article links: Changes in asthma severity in the first year of school and difficulty learning to read. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. Sialylation of immunoglobulin E is a determinant of allergic pathogenicity. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	09 Sep 2020	Episode 13, Part 2 – Delayed Drug Hypersensitivity with Dr. David Khan, MD	00:17:49
Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org! The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.
	15 May 2019	Episode 1	00:47:07
With guest Stanley Fineman, MD, MBA, FACAAI, editor-in-chief of AllergyWatch.
	23 Jul 2019	Episode 2: Asthma	00:37:24
For today’s episode we will be reviewing three articles about asthma from the May-June 2019 issue of Allergy Watch: Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. https://www.ncbi.nlm.nih.gov/pubmed/30217529 Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. https://www.ncbi.nlm.nih.gov/pubmed/30205189 Indirect Treatment Comparisons and Biologics https://www.ncbi.nlm.nih.gov/pubmed/30612667 Endotypes of severe allergic asthma patients who clinically benefit from anti?IgE therapy https://www.ncbi.nlm.nih.gov/pubmed/30107059/ Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma https://www.ncbi.nlm.nih.gov/pubmed/29301922 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from Astra Zenica. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire Research: Aimmune, DBV, Shire, Regeneron.
	23 Jul 2019	Episode 3: Food Allergy & Eczema	00:28:51
For today’s episode we will be reviewing three articles about food allergy and eczema from the May-June 2019 issue of Allergy Watch: The Basophil Activation Test reduces the need for a food challenge test in children suspected of IgE-mediated cow's milk allergy. https://www.ncbi.nlm.nih.gov/pubmed/30408255 Oral food challenge failures among foods restricted because of atopic dermatitis. https://www.ncbi.nlm.nih.gov/pubmed/30326323 The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype. https://www.ncbi.nlm.nih.gov/pubmed/30787169 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from Astra Zenica. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire Research: Aimmune, DBV, Shire, Regeneron.
	02 Oct 2019	Episode 4: Dupliumab for Nasal Polyps, Cockroach Immunotherapy and Immediate Food Allergy in EoE	00:36:45
For today’s episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch: Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis https://www.ncbi.nlm.nih.gov/pubmed/30488542 Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity https://www.ncbi.nlm.nih.gov/pubmed/30170124 New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis https://www.ncbi.nlm.nih.gov/pubmed/30684739 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from AstraZeneca. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
	29 Oct 2019	Episode 6: Telemedicine in allergy/immunology	00:29:32
We are excited to present a special episode of Allergytalk! Dr. Jennifer Shih, MD joins the podcast to discuss the use of telemedicine in allergy/immunology! Please give us feedback, corrections, and suggestions! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from AstraZeneca. Dr. Shih was on advisory board for Teva and Tekeda.
	20 Jun 2024	Episode 34: Are Nasal Polyps an Autoimmune Disease?	00:22:57
Originally Recorded 4/18/2023 Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Articles Reviewed: Combined ICS/SBA Reduces Asthma Exacerbations Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. CRSwNP Patients have Impaired Sense of Smell and Taste Improvement in patient-reported "taste" and association with smell in dupilumab -treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS -24 and SINUS -52 trials. Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life. Anti-dsDNA IgG May Predict Nasal Polyp Recurrence Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Joshi has the following disclosures: Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent Clinical trial funding: GlaxoSmithKline Sanofi Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	09 Jul 2024	Episode 40 – Intranasal Epinephrine for Anaphylaxis	00:20:54
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly: An integrated analysis. Wildfires and the Changing Landscape of Air Pollution-related Health Burden in California. Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Chow have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
	16 Jul 2024	Episode 42 – What’s the Best Antibiotic for Kids With Sinusitis?	00:21:12
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: The protective effect of moderate maternal peanut consumption on peanut sensitization and allergy. Hymenoptera venom skin testing: Adopting an accelerated test protocol. Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Spriet have nothing to disclose Dr. Fineman - Research: DBV, Novartis, Alladapt

Enhance your understanding of allergytalk with My Podcast Data

At My Podcast Data, we strive to provide in-depth, data-driven insights into the world of podcasts. Whether you're an avid listener, a podcast creator, or a researcher, the detailed statistics and analyses we offer can help you better understand the performance and trends of allergytalk. From episode frequency and shared links to RSS feed health, our goal is to empower you with the knowledge you need to stay informed and make the most of your podcasting experience. Explore more shows and discover the data that drives the podcast industry.

About us Privacy Policy